Case Law Details
Maneesh Pharmaceuticals Ltd Vs Export Import Bank of India and Ors (Supreme court of India)
Introduction: The recent Supreme Court judgment in the case of Maneesh Pharmaceuticals Ltd vs. Export Import Bank of India and Ors sheds light on the interplay between the National Company Law Tribunal (NCLT), National Company Law Appellate Tribunal (NCLAT), and the Insolvency and Bankruptcy Code (IBC) Section 7 petitions. The appeal arises from an order of the NCLAT, raising crucial questions about the evaluation of rival contentions on merits before admitting petitions under Section 7 of the IBC.
Detailed Analysis: The case began with the dismissal of the application under Section 7 of the IBC by the NCLT on the grounds of limitation. While dismissing the petition based on limitation, the NCLT made observations on merits. The NCLAT later set aside the NCLT’s order, stating that the finding of limitation was “patently illegal.” However, it also acknowledged the absence of dispute regarding the Corporate Debtor’s liability towards the Financial Creditors and the guarantee by the Respondent.
The appeal to the Supreme Court followed, leading to the dismissal of the appeal on July 4, 2023. Subsequently, the respondents sought restoration of the application under Section 7 before the NCLT, which was allowed on July 5, 2023. The NCLT’s order declining to adjourn proceedings and the subsequent appeal before the NCLAT, resulting in the direction to admit the application under Section 7, forms the crux of the current appeal.
The Supreme Court’s analysis emphasizes that the NCLAT’s direction to admit the application under Section 7 without evaluating rival contentions on merits was inappropriate. The court clarifies that the NCLAT’s earlier observations on the dispute were in the context of the limitation issue and should not be considered a conclusive determination on the admission of the petition. The judgment underscores the need for a comprehensive assessment of rival contentions before admitting a petition under Section 7.
Please become a Premium member. If you are already a Premium member, login here to access the full content.
Author Bio
